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Autoantibodies in leprosy patients, with and without 
joint involvement, in the state of Amazonas
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ABSTRACT
Objective: Determine the frequency of rheumatoid factor (IgM-RF) and anti-cyclic citrullinated peptide antibodies 
(anti-CCP), antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), anticardiolipin antibodies 
(aCL), and anti-β2 glycoprotein I antibodies (anti-β2GPI) in leprosy patients, with and without joint involvement, and to 
evaluate the possible association among those antibodies and articular manifestations, clinical type, reactional episodes, 
polychemotherapic treatment (PCT), and discharge from PCT. Patients and methods: One hundred and fifty-eight leprosy 
patients were divided in two groups of 73 patients (Group I) and 82 patients (Group II). Group III was composed of 129 
healthy individuals. Methods: Semi-quantitative latex agglutination test for IgM-RF, indirect immunofluorescence for 
ANA and ANCA, and ELISA for anti-CCP, aCL, and anti-β2GPI. Results: Fifty-six (35.4%) of 158 leprosy patients had 
lepromatous leprosy (LL). The frequency of anti-CCP, RF, and ANA antibodies in Groups I and II was similar to that of 
Group III. Antineutrophil cytoplasmic antibodies were not detected in any patient. Anticardiolipin antibodies were more 
frequent in leprosy patients (Groups I and II) than in control group (15.8% vs. 3.1%; P < 0.001), and differences between 
Groups I and II (P = 0.67) were not observed. Anti-β2GPI antibodies were also more common in leprosy patients than 
in control group (46.2% vs. 9.4%; P < 0.001), without differences between Groups I and II. A predominance of IgM 
isotype over IgG isotype was observed both for aCL (88% vs. 16%; P = 0.001) and anti-β2GPI (97.3% vs. 12.3%; P < 
0.001). Patients did not present manifestations suggestive of vascular thrombosis. Conclusion: The frequency of aCL 
and anti-β2GPI antibodies was significantly increased in leprosy patients than in healthy individuals. However, positivity 
to other autoantibodies was similar to that observed in the control group. An association between autoantibodies and 
joint involvement, reactional episodes, polychemotherapic treatment, discharge, and clinical type of leprosy was not 
observed, except for aCL antibodies, which were more frequent in lepromatous leprosy.
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INTRODUCTION
Leprosy is an infectious disease caused by Mycobacterium 
leprae, which is responsible for a wide spectrum of clinical 
manifestations that depend on the immune response of 
the host.1 The classification of this disease is based on the 
immunological, histological, and microbiological parameters 
described by Ridley & Jopling.2 In tuberculoid leprosy, the 
host has an efficient cell-mediated immune response, while 
lepromatous leprosy is characterized by humoral immunity. 
Borderline types that reflect the gradual variation in resistance 
to the bacillus are between those extremes.2
Joint involvement is considered the third most common 
manifestation in leprosy, after dermatologic and neurological 
manifestations. The frequency of articular manifestations 
reported ranges from 1% to 78%.3-5 This wide variability 
can, occasionally, be attributed to patient selection. Joint 
involvement can manifest as symmetrical polyarthritis of small 
and large joints, simulating rheumatoid arthritis.4,7,8
Besides the wide variability in the prevalence of the 
different autoantibodies in patients with leprosy reported in 
the literature, there are few studies correlating the presence of 
autoantibodies and joint manifestations of this disease.4,9,11,12 
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In leprosy, the presence of autoantibodies associated with 
systemic manifestations similar to those of rheumatic diseases 
can hinder its diagnosis.
Considering that leprosy is among the differential diagnosis 
of rheumatic diseases, this study was designed to determine 
the frequency of rheumatoid factor (IgM-RF) and anti-cyclic 
citrullinated peptide antibodies (anti-CCP), antinuclear 
antibodies (ANA), antineutrophil cytoplasmic antibodies 
(ANCA), anticardiolipin antibodies (aCL), and anti-β2 
glycoprotein I antibodies (anti-β2GPI) in patients with leprosy, 
with or without joint involvement, with similar age, gender, 
and disease-related characteristics, and to study the possible 
association among those autoantibodies and joint involvement, 
clinical type, reactional episodes, polychemotherapic treatment 
(PCT), and discharge from PCT.
PATIENTS AND METHODS
A transversal descriptive study with 158 patients with the 
diagnosis of leprosy seen regularly at the Dermatology and 
STDs Outpatient Clinic of the Fundação Alfredo da Mata 
(FUAM) in Manaus, Brazil, from June 2004 to October 2006 
was undertaken. All patients had diagnosis of leprosy according 
to the classification of Ridley & Jopling (1966).2 Leprosy was 
classified as: undetermined (U), tuberculoid (TT), borderline 
tuberculoid (BT), borderline borderline (BB), borderline 
lepromatous (BL), and lepromatous (LL).
During routine follow-up, patients who complained 
of articular pain were referred for evaluation with two 
rheumatologists (SLER and HLAP) who did a detailed 
history and physical exam to characterize the extension of 
the joint involvement and determine the presence of any 
other clinical manifestation. Patients with rheumatic diseases 
or neuropathic arthropathy were excluded from the study. 
Complementary exams were requested for patients with 
chronic arthropathy to exclude rheumatoid arthritis and 
seronegative spondyloarthropathies. Joint involvement was 
classified as: arthritis (presence of swelling and tenderness on 
palpation and movement) or arthralgia (pain on motion, but 
no other signs of inflammation).
Initially, 76 leprosy patients with joint involvement were 
identified, forming Group I. Afterwards, 82 leprosy patients 
without joint involvement (Group II), matched for age, gender, 
and characteristics of leprosy to Group I, were selected. Group 
III (control group) was formed by 129 healthy individuals, 
matched to Groups I and II in age and gender, recruited among 
health professionals, professors, students, and workers at 
FUAM in Manaus (AM, Brazil).
Data on leprosy, gathered on the interview and review of 
the medical records, as well as clinical findings, were recorded 
on a standardized form and included in a computer data base 
(Excel, 2003, Microsoft®). Patients and controls were asked 
specifically about any history of vascular thrombosis (arterial 
or venous).
This study was approved by the Ethics Committees from 
Fundação Pedro Matta (FUAM) – number 009/04 and from 
Universidade Federal de São Paulo (UNIFESP) – number 
1282/07, and all study subjects signed an informed consent.
LABORATORY EXAMS
To determine the presence of autoantibodies, 20 mL of peri-
pheral venous blood were collected from all subjects. After 
being centrifuged, the serum was divided in aliquots and stored 
at -70°C at the FUAM laboratory for posterior analysis at the 
rheumatology laboratory of UNIFESP.
The presence of IgM-RF was evaluated by semi-quantitative 
latex agglutination using the commercially available RapiTex 
RF kit (Dade Behring, Marburg, Germany), according to the 
instructions of the manufacturer. Titers above 20 IU/mL were 
considered positive.
To detect anti-CCP, the commercially available Immunoscan 
RA Anti-CCP2 kit (RA-96RT- Eurodiagnostics, Malmö, 
SE) was used according to the recommendations of the 
manufacturer, and titers ≥ 25 U/mL were considered positive.
Antinuclear antibodies were detected by indirect 
immunofluorescence (IIF) using a commercially available 
kit (BION, Enterprises, Ltda., USA) that uses HEp-2 cells, 
as the substrate, and anti-human immunoglobulin antibody 
conjugated with fluorescein, according to the specifications 
of the manufacturer. The exam was read by two experienced 
observers who did not know the origin of the sera.
Sera that tested positive for ANA on IIF were also tested 
by double immunodiffusion to identify the specificity. In 
summary, double diffusion in agarose plates was performed 
using extract of veal spleen as antigen, to detect anti-U1-RNP, 
anti-SS, anti-SS-A/Ro and anti-SS-B/La antibodies, and extract 
of rabbit thymus, to detect anti-Jo-1 and anti-Scl-70 antibodies. 
Standard sera with known specificity were used to compare 
precipitation lines.
The presence of anti-dsDNA antibodies was also evaluated 
in sera positive for ANA using IIF with Crithidia luciliae as 
substrate. Slides were prepared from a culture of C. luciliae, 
according to the standard technique of the laboratory. Sera were 
tested at the initial dilution of 1:5 and read on a fluorescence 
microscope (Olympus BX50) with a 400x power.
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The presence of ANCA was determined by IIF using 
peripheral blood neutrophils, fixed and permeated according 
to the standard in house technique.13 All sera were tested at an 
initial dilution of 1:20.
The presence of aCL antibodies was determined by ELISA, 
in plaques prepared according to the routine of the laboratory, 
using international standards (Louisville APL Diagnostics, Inc, 
Doraville, USA, Prod#LAPL-GM100 IgG/IgM Calibrators). 
Levels above 20 GPL and 10 MPL for IgG and IgM aCL 
antibodies, respectively, were considered positive. Those 
results were obtained by calculating the 95% percentile of 200 
blood donor samples analyzed in the same laboratory.
The presence of anti-β2GPI IgG and IgM antibodies was 
detected by ELISA, using commercial kits (BINDAZYME 
Human Anti-β2GPI IgG and Anti-β2GPI IgM, The Binding 
Site, Birmingham, UK) according to the instructions of the 
manufacturer. Results above 20 U/mL, for anti-β2GPI IgG 
antibodies, and 10 U/mL, for anti-β2GPI IgM antibodies, were 
considered positive.
STATISTICAL ANALYSIS
The SPSS 15.0.1 software (Chicago, USA) was used to 
analyze the data. Mean, median, and standard deviation (SD) 
were used for the descriptive analysis of quantitative data, 
minimal and maximal values for continuous parameters, and 
proportions for categorical parameters. Student t test was used 
to compare continuous parameters with normal distribution, 
according Kolmogorov-Smirnov test, among the study groups; 
and for parameters that did not show normal distribution, the 
non-parametric Mann-Whitney and Kruskal-Wallis tests were 
used. Pearson’s Chi-square test, Fisher’s Exact test, and the 
binominal test were used for categorical parameters. P-values 
< 0.05 were considered statistically significant.
RESULTS
Demographic and Clinical Data
Leprosy patients had a mean age of 39.9 ± 15.2 years; 113 (71.5%) 
were males men and 45 (28.5%) females women (P = 0.001). 
Regarding polychemotherapy, 40.5% were being treated and 
59.5% had been discharged from PCT. Reactional episodes were 
observed in 36.7% of the patients at the moment of the study, and 
the LL type, seen in 56 (35.4%) patients, was more common. 
Demographic data and clinical characteristics of leprosy were 
similar in Groups I and II. Erythema nodosum leprosum was the 
most common reaction observed in both groups (Table 1).
The distribution of clinical types between Groups I and II 
(P = 0.938) did not show significant differences, and the LL 
type was the most frequent in both (Figure 1).
Sixty-one (80.3%) of 76 patients with joint involvement 
(Group I) had arthritis and 15 (19.7%) arthralgia. Most common 
joint involvement patterns included polyarthralgia (13/15) and 
polyarthritis (46/61). Among the 61 patients with arthritis, 65.6% 
did not present reactional episodes at the time of the study.
Figure 1. Distribution of leprosy patients in Groups I and II according 
to the clinical type.
Table 1
Demographic parameters, length of the disease, 
use of polychemotherapy (PCT), and reactional 
episodes in leprosy patients, with and without 
joint involvement (Groups I and II)
Patients’ characteristics
(n = 158)
Group I
n = 76 
(48.1%)
Group II
n = 82 
(51.9%) P
Gender
Male
Female
51 (67.1)
25 (32.9)
62 (75.6)
20 (24.4)
0.237
Age (years)
Mean (SD) 39.8 (15.77) 40.06 (14.81) 0.716*
Length of disease
Mean (SD) in months 39.4 (32.4) 32.2 (33.0) 0.124*
PCT
Discharged
Being treated
50 (65.8)
26 (34.2)
44 (53.7)
38 (46.3)
0.121
Reactional Episodes
Present
Absent
24 (31.6)
52 (68.4)
34 (41.5)
48 (58.5)
0.198
Type of Reaction
Type 1
Type 2
Isolated Neuritis
7 (29.2)
16 (66.7)
1 (4.2)
8 (23.5)
22 (64.7)
4 (11.8)
0.570
Pearson’s Chi-square test. Mann-Whitney test*
Pa
tie
nt
s
 Group I (n = 76)      Group II (n = 82)
45 %
40 %
35 %
30 %
25 %
20 %
15 %
10 %
5 %
0 %
U TT BT BB BL LL
2.6 2.4 2.6
4.9
21.1
19.5
15.8 15.3
18.7
24.4
38.2
32.9
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In the control group, out of 129 patients, 59.7% were men 
and 40.3% women, with a mean age of 40.9 ± 14.1 years. The 
age and gender distribution of this group was similar to that 
of groups I and II (P = 0.611 and P = 0.057).
LABORATORY EXAMS
IgM-RF was positive in only two (1.2%) out of 158 leprosy 
patients, with titers of 80 and 160 IU/mL. Both patients with 
positive IgM-RF were in Group I, males, and had polyarthritis. 
In the control group, three of 129 (2.3%) healthy individuals 
had positive IgM-RF, two with low titers (80 IU/mL) and one 
with a high titer (1280 IU/mL). The frequency of IgM-RF 
did not show significant differences among the three groups 
(P = 0.357).
Anti-CCP antibodies were positive in only 4 patients 
(2.5%), whose titers ranged from 27 to 34 U/mL and none 
of them had joint involvement. All four patients were males, 
one had LL and the other three, borderline leprosy (BL, BB, 
BT). At the time of the study, two of those patients presented 
reactional episodes, being treated with prednisone, and three 
had been discharged from PCT. For anti-CCP antibodies, 89 
sera were tested in Group III, of which three were positive, 
two with low to moderate titers (44 and 53 U/mL) and one 
with a high titer (1827 U/mL). Anti-nuclear antibodies were 
positive in six (3.8%) of 158 patients with leprosy (2.6% in 
Group I and 4.9% in Group II) and in eight of 129 (6.2%) in 
Group III. Fine speckled nuclear pattern, with titers between 
1/80 and 1/320, was seen in the sera of six patients and seven 
controls. One control showed nuclear envelope pattern with 
a titer of 1/640. As for the classification of leprosy of patients 
with positive ANA, one had LL, four borderlines, and one TT. 
Three of those patients had reactional episodes.
A known specificity was not identified in the sera of patients 
and control individuals ANA-positive by IIF, since precipitation 
lines were not observed in double immunodiffusion and the 
sera were negative for anti-dsDNA.
Antineutrophil cytoplasmic antigen was not detected in 
any of the patients and control individuals.
As for antiphospholipid antibodies (aFL), the frequency 
of aCL antibodies (P = 0.67) and anti-β2GPI antibodies 
(P = 0.5) did not differ between Groups I and II. However, the 
prevalence of aCL and anti-β2GPI antibodies was significantly 
higher in leprosy patients (Groups I and II) than in healthy 
controls (15.8% vs. 3.1%; P < 0.001 and 46.2% vs. 9.4%; 
P < 0.001, respectively).
Seventy-seven (48.7%) of 158 leprosy patients were 
positive for at least one of the aFL antibodies investigated 
(aCL and/or anti-β2GPI). Considering all leprosy patients, 
a difference in the distribution of the clinical forms among 
those who tested positive and negative for aCL antibodies was 
observed (P = 0.002). In patients with aCL antibodies, the LL 
type was more common (72%) than the other types (P = 0.001), 
while in those negative for aCL a predominance of a clinical 
type was not observed. Differences in the distribution of the 
clinical types among patients who were positive and negative 
for anti-β2GPI (P = 0.088) was not observed.
The presence of aFL antibodies did not show differences 
among patients with or without reactional episodes, both for 
aCL (19.0% vs. 14.0%; P = 0.41) and anti-β2GPI (51.7% vs. 
43%; P = 0.28). However, considering the 58 patients with 
reactional episodes, a significant difference in the proportion 
of the types of reactions among patients who were positive 
and negative for aCL antibodies (P = 0.028) was observed. All 
patients aCL positive presented erythema nodosum leprosum, 
while this reaction was present in 57.4% of those who were 
aCL negative. In patients with anti-β2GPI this difference was 
not observed (P = 0.17).
The presence of aCL antibodies and anti-β2GPI did 
not differ among patients in PCT and those who had been 
discharged from it (18.8% vs. 13.8%; P = 0.40 and 37.5% vs. 
52.1%, respectively).
Titers above 40 U/mL were observed in 80% (20/25) of the 
patients with aCL antibodies and in 35.6% (26/73) of patients 
with anti-β2GPI antibodies, but not in healthy individuals. 
Mean aFL antibody levels in leprosy patients (Groups I and 
II) were 57 GPL and 56 MPL, for aCL antibodies, and 112 
U/mL, for IgG, and 94 U/L, for IgM, anti-β2GPI antibodies.
As for aFL antibodies (aCL and anti-β2GPI), the IgM 
isotype was more common both in leprosy patients and healthy 
controls. Out of 25 patients aCL positive, 88% presented 
the IgM isotype and 16% IgG (P < 0.001). The four healthy 
individuals who tested positive for aCL had IgM isotype 
antibodies. Out of 73 patients positive for anti-β2GPI, 97.3% 
presented the IgM isotype and 12.3% IgG (P < 0.001). In the 
control group, 90% of anti-β2GPI antibodies were IgM and 
10% IgG (P < 0.001).
Table 2 shows the frequency of the different autoantibodies 
in Groups I, II, and III.
Both patients and healthy individuals had a negative history 
for arterial and venous thrombosis.
DISCUSSION
Brazil has the second higher prevalence of leprosy in the 
world.14 Leprosy is one of the differential diagnoses of 
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rheumatic diseases, since autoantibodies and articular and 
systemic manifestations can be seen in both situations. The 
present study included patients seen in the outpatient clinic 
of a reference center for the treatment of leprosy in the state 
of Amazonas, in northern Brazil, including a large number 
with and without joint involvement, different clinical types, 
and different stages of the disease. The choice of the control 
group, composed of healthy individuals living in the same 
region, was oriented by the possibility of inhabitants of areas 
more exposed to infections presenting greater positivity of one 
of the autoantibodies.15
A study with similar design was not found in the literature. 
Few studies that evaluated rheumatic complaints included 
manifestations like enthesitis and erythema nodosum leprosum, 
besides arthritis and arthralgia,14,9,11,12 and only two studies 
evaluated a set of autoantibodies, but without evaluating the 
correlation with joint involvement.16,17
In the present study, joint involvement was predominantly 
polyarticular and most patients did not have active reaction, 
similar to the findings of other authors.4,10,12
In this study, 80 out of 158 (50.6%) leprosy patients were 
positive for at least one of the autoantibodies investigated. The 
frequency of IgM-RF, anti-CCP, ANA, and ANCA in leprosy 
patients was low and similar to that of the control groups. 
However, the prevalence of aCL antibodies and anti-β2GPI 
antibodies was significantly higher in leprosy patients than in 
the control group. An association between the presence of any 
antibody and articular involvement in leprosy was not observed.
Several studies indicate an increased frequency of 
autoantibodies in leprosy; however, the percentage reported 
varies considerably.4,12,16-24
This variability can be attributed to different selection 
criteria, genetic background of the study population, and 
techniques used to detect autoantibodies. One should also 
consider the possible presence of associated infectious diseases 
in some of those series.15
The presence of autoantibodies has been reported especially 
in multibacillary LL, which has marked humoral immune 
response. In paucibacillary tuberculoid leprosy, the cellular 
immune response is effective and the presence of autoantibodies 
is less common.25 However, the origin of autoantibodies in 
leprosy and in other chronic infectious diseases has not been 
established; it might be due to the polyclonal activation of B 
cells by bacterial components,26,27 presence of cross reaction 
between bacterial antigens and autoantigens,4,21 or to chronic 
tissue injury and exposure of antigens that are usually occult.
In the present study, the low prevalence of IgM-RF in 
leprosy patients did not allow the analysis of associations 
with reactional state and clinical type. In the literature, the 
prevalence of IgM-RF in leprosy patients varies considerably. 
Frequencies between 28 and 58%, especially in the LL 
type, have been reported by several authors;9,10,12,18 however, 
frequencies lower than 6%, similar to our results, have also 
been reported.11,20,21 Some authors found an association between 
IgM-RF and arthritis,9,28 which has not been corroborated by 
other studies,4,10-12 including ours.
Table 2
Frequency of the different autoantibodies in leprosy patients with (Group I) and without 
(Group II) joint involvement and healthy individuals (Group III)
AUTOANTIBODIES
Group I (n = 76) Group II (n = 82) Group III (n = 129) 
Pn (%) n (%) n (%)
IgM-RF 2  (2.6) 0  (0.0)  3   (2.3) 0.357
Anti-CCP 0  (0.0) 4  (4.9)  3   (3.4) * 0.169
ANA 2  (2.6) 4  (4.9)  8  (6.2) 0.519
ANCA 0  (0.0) 0  (0.0)  0  (0.0)
aCL-GPL 1  (1.3) 3  (3.7)  0  (0.0)
aCL-MPL 12 (15.8) 10 (12.2)  4  (3.1)
aCL 13 (17.1) 12 (14.6)  4  (3.1) 0.002.
anti-β2GPI IgG 4  (5.3) 5  (6.1) 1  (0.9)**
anti-β2GPI IgM 33 (43.4) 38 (46.3) 9  (8.5)**
anti-β2GPI 33 (43.4) 40 (48.8) 10  (9.4)** < 0.001
Anti-CCP = anti-cyclic citrullinated antibodies; IgM-RF = rheumatoid factor; ANA = antinuclear antibodies; ANCA = antineutrophil cytoplasmic 
antibodies; aCL = anticardiolipin antibodies; anti-β
2
GPI = anti-β
2
glicoprotein I antibodies. n=89* n=106**
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Anti-CCP antibodies are considered highly specific for 
the diagnosis of rheumatoid arthritis;29 however, very few 
studies evaluating the presence of anti-CCP antibodies in 
infectious diseases have been reported. Anti-CCP antibodies 
were found in up to 8.8% of the patients with hepatitis C.30,31 
In two independent studies, relatively high frequencies, 32 
and 37%, of anti-CCP antibodies were found in patients with 
active tuberculosis without associated joint involvement.32,33
In the present study, we found a low frequency of anti-
CCP antibodies in leprosy patients with or without joint 
involvement.34 Those data corroborate the results of Guedes-
Barbosa et al.,35 who also found low frequencies of anti-
CCP antibodies in leprosy patients. However, those authors 
evaluated only 64 patients, without referring whether they had 
joint involvement and without a control group with healthy 
individuals.
In this study, we observed a low frequency of ANA in 
leprosy patients, similar to that of the control group, and 
without an association with joint involvement. Although the 
results of the present study do not agree with the high positivity 
reported by some authors,12,26 it is similar to the results reported 
in several studies.4,11,21,22 We emphasize that, with the exception 
of the study of Dacas et al.12 with 120 patients, the remaining 
studies had a small population, with less than 60 patients.
In this study, anti-dsDNA antibodies and antibodies against 
extractable nuclear antigens were negative both in leprosy 
patients and healthy controls. Studies that identified those 
antibodies used ELISA, which has greater sensitivity, but 
whose specificity depends on the set of reagents, especially 
the antigen used.16,17
As for the clinical type of leprosy, Miller et al.21 observed 
a higher percentage of ANA in the bacillary type, contrasting 
with the results of Bonfá et al.26 who demonstrated a higher 
positivity in the paucibacillary type. There is also a study 
demonstrating a similar frequency in both clinical types.12 
Some authors reported a greater prevalence of ANA in patients 
with erythema nodosum leprosum.21 In the present study, 
the low positivity of ANA did not allow the analysis of its 
relationship with the clinical type and reactional episodes.
We did not observe the presence of ANCA in the serum 
of leprosy patients or controls, corroborating prior studies.16,36 
However, some authors reported the presence of ANCA, 
ranging from 5 to 32%, in leprosy patients.7,17,24,27,37 Recently, 
it has been suggested that testing for ANCA, recommended 
in developed countries as a subsidiary test in pauci-immune 
vasculitis, such as Wegner’s granulomatosis, Churg Strauss 
syndrome, and polyarteritis nodosa, should not be done in 
regions with a high prevalence of infectious diseases like 
malaria, leprosy, and tuberculosis.38 This recommendation 
was justified since the test can be positive in 19 to 32% of 
patients with those infections. The absence of those antibodies 
in our study, in which they were evaluated in a large number 
of patients and healthy controls in a region in which those 
infections are endemic, does not support this recommendation.
In the presence of an infectious process, antiphospholipid 
antibodies could be induced by subtle disturbances in the 
regulation of humoral and cellular immunity or, alternatively, 
their development could be secondary to the exposure of 
phospholipid antigens during the inflammatory process 
secondary to the infection. Currently, the most accepted 
hypothesis for the development of those antibodies in infectious 
processes is that infections trigger the induction of pathogenic 
aFL in genetically predisposed individuals.39,40 In this case, 
bacterial or viral antigens, with a sequence homologous to that 
of β2GPI, would be presented to T lymphocytes that stimulate 
B lymphocytes to produce antibodies against the heterologous 
sequence, which would cross react with the β2GPI of the 
individual.40,41
We found a lower incidence of β2GPI cofactor-dependent 
aCL antibodies (15.8%) than those reported by other authors 
(29% to 98%), who also used ELISA.19,23,39,42-47 A higher 
frequency of aCL antibodies was observed in patients with 
multibacillary LL, as reported by several studies.19,23,44,45,47 
We observed titers above 40 U/mL in 80% of leprosy patients 
positive for aCL antibodies, in agreement with prior studies.23,47
Corroborating other studies,23 we also observed a 
predominance of the IgM isotype in aCL antibodies of leprosy 
patients. We did not find an association between the presence 
of aCL antibodies and joint involvement or reactional episodes. 
However, we observed that all patients with a reactional 
episode who were positive for aCL antibodies presented 
erythema nodosum leprosum. We found only one study in the 
literature, evaluating a small number of patients, all with the 
borderline leprosy, in which the presence of high titers of aCL 
antibodies was associated with an increased risk of reactional 
episodes.42
Some studies suggest that anti-β2GPI antibodies would 
represent more specific markers of antiphospholipid syndrome 
(APS), presenting a greater association with the typical 
complications of APS and lower frequency of infectious 
diseases.48 However, in leprosy, anti-β2GPI antibodies were 
found in up to 89% of the patients.
In the present study, we observed a high prevalence of 
anti-β2GPI antibodies in leprosy patients (46.2%), without 
association with the clinical type. The IgM isotype was the 
most frequent, similar to the reports of other authors.23,29 
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However, Arvieux et al.,45 studying patients with multibacillary 
LL, did not observe a predominance of one isotype. Similar 
to other antibodies, we did not observe an association among 
the presence of anti-β2GPI and joint involvement, reactional 
episodes, or type of reaction.
Although the literature has studies referring a higher 
incidence of aCL antibodies than anti-β2GPI antibodies in 
leprosy,19,43 in our study, the frequency of anti-β2GPI was 
higher, which is in agreement with the results of Loizou et al.39 
Those authors reported a predominance of the IgA isotype, in 
the tests for aCL antibodies, and IgM isotype, for anti-β2GPI. 
In the present study, the IgA isotype was not evaluated and the 
IgM isotype was the most frequent in both tests.
In our study, 84% of the leprosy patients positive for aCL 
antibodies also presented anti-β2GPI antibodies and, in 71% 
of those patients, those antibodies, of the IgM isotype, were 
present in titers higher than 40 U/m. Despite the high frequency 
of aFL, corroborating the data in the literature, we did not 
find an association between those antibodies and thrombotic 
manifestations.23,39,45,46 Although there are reports of cases 
associating IgM aCL antibodies with thrombotic phenomena 
in leprosy patients,49,50 it is possible that those cases represent 
a coincidence, since the clinical meaning of those antibodies 
is not clear in this disease.
To conclude, the frequency of RF, ANCA, ANA, and anti-
CCP antibodies in leprosy patients was low and did not show 
an association with joint involvement, clinical type, or the 
presence of reactional episodes. We found a high prevalence of 
aCL antibodies and, especially, anti-β2GPI antibodies in leprosy 
patients, with a predominance of the IgM isotype; however, they 
were not associated with thrombotic manifestations. It is possible 
that the presence of aFL in leprosy constitutes just another 
marker of autoimmunity. It would be interesting to undertake a 
study with longitudinal follow-up of leprosy patients to evaluate 
the persistence of those autoantibodies, as well as the study of 
the fine specificity of those antibodies in comparison to those 
observed in the antiphospholipid syndrome.
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